Eyeing high-margin therapeutics, reagent provider collaborates with material producer - will it work?

June 25, 2013 | Analyst Insight

A milestone and royalty-based therapeutics development and commercialization licensing agreement inked last week raised an eye here at Lux, not because it was a particularly large deal, but because...